Clinical Trials Logo

Central Nervous System Neoplasms clinical trials

View clinical trials related to Central Nervous System Neoplasms.

Filter by:

NCT ID: NCT00004212 Completed - Lymphoma Clinical Trials

DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas

Start date: September 1999
Phase: Phase 1
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of DX-8951f in treating children who have advanced solid tumors or lymphomas that have not responded to previous therapy.

NCT ID: NCT00004200 Completed - Clinical trials for Brain and Central Nervous System Tumors

Prinomastat Plus Temozolomide Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Start date: October 1999
Phase: Phase 2
Study type: Interventional

RATIONALE: Prinomastat may stop the growth of glioblastoma multiforme by stopping blood flow to the tumor. Drugs used in chemotherapy stop tumor cells from dividing so they stop growing or die. PURPOSE: Randomized phase II trial to study the effectiveness of prinomastat plus temozolomide in treating patients who have newly diagnosed glioblastoma multiforme.

NCT ID: NCT00004147 Completed - Clinical trials for Brain and Central Nervous System Tumors

COL-3 in Treating Patients With Progressive or Recurrent Brain Tumors

Start date: July 2000
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: COL-3 may stop the growth of brain tumors by stopping blood flow to the tumor. PURPOSE: Phase I/II trial to study the effectiveness of COL-3 in treating patients who have progressive or recurrent brain tumors following radiation therapy or chemotherapy.

NCT ID: NCT00004113 Completed - Clinical trials for Brain and Central Nervous System Tumors

Temozolomide in Treating Patients With Recurrent Malignant Glioma

Start date: June 1999
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of temozolomide in treating patients who have recurrent malignant glioma.

NCT ID: NCT00004080 Completed - Clinical trials for Brain and Central Nervous System Tumors

Gene Therapy in Treating Patients With Recurrent or Progressive Brain Tumors

Start date: December 1999
Phase: Phase 1
Study type: Interventional

RATIONALE: Inserting the gene for p53 into a person's brain cells may improve the body's ability to fight cancer. PURPOSE: Phase I trial to study the effectiveness of p53 gene therapy with SCH-58500 in treating patients who have recurrent, or progressive glioblastoma multiforme, anaplastic astrocytoma, or anaplastic mixed glioma that can be removed during surgery.

NCT ID: NCT00004073 Completed - Clinical trials for Brain and Central Nervous System Tumors

Suramin Plus Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Start date: December 1999
Phase: Phase 2
Study type: Interventional

RATIONALE: Suramin may stop the growth of glioblastoma multiforme by stopping blood flow to the tumor. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining suramin with radiation therapy may be a more effective treatment for glioblastoma multiforme. PURPOSE: Phase II trial to study the effectiveness of suramin plus radiation therapy in treating patients who have newly diagnosed glioblastoma multiforme.

NCT ID: NCT00004068 Completed - Clinical trials for Brain and Central Nervous System Tumors

Irinotecan Followed by Radiation Therapy and Temozolomide in Treating Children With Newly Diagnosed Brain Tumor

Start date: March 1999
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with radiation therapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of irinotecan followed by radiation therapy and temozolomide in treating children who have newly diagnosed brain tumor.

NCT ID: NCT00004041 Completed - Clinical trials for Brain and Central Nervous System Tumors

Gene Therapy in Treating Patients With Recurrent Malignant Gliomas

Start date: February 25, 1999
Phase: Phase 1
Study type: Interventional

RATIONALE: Inserting the gene for adenovirus p53 into a person's tumor may improve the body's ability to fight cancer. PURPOSE: Phase I trial to study the effectiveness of gene therapy in treating patients who have recurrent malignant gliomas.

NCT ID: NCT00004028 Completed - Clinical trials for Brain and Central Nervous System Tumors

Carmustine in Treating Patients With Recurrent Malignant Glioma

Start date: September 1996
Phase: Phase 1
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of carmustine in treating patients who are undergoing surgery for recurrent malignant glioma.

NCT ID: NCT00004024 Completed - Clinical trials for Brain and Central Nervous System Tumors

Biological Therapy Following Surgery and Radiation Therapy in Treating Patients With Primary or Recurrent Astrocytoma or Oligodendroglioma

Start date: June 1997
Phase: Phase 2
Study type: Interventional

RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Combining different types of biological therapies may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of biological therapy following surgery and radiation therapy in treating patients who have primary or recurrent astrocytoma or oligodendroglioma.